# Neurolens

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neurolens

- Industry: Medical Devices & Equipment
- Headquarters: Coppell, US
- Website: www.neurolens.com
- Total disclosed funding: $68M
- Latest round: Series E (Sep 1, 2022)
- Investors on record: 3

## About

Neurolens, Inc. develops innovative eye care solutions focused on treating eye misalignment through advanced lens technology, aiming to enhance visual comfort and alleviate related symptoms for patients across various regions.Founded in 2012 in Coppell, Texas, Neurolens, Inc. specializes in addressing eye misalignment through its unique lens technology. The company has completed a total of 7 deals, with its latest funding round being a GROWTH round that raised USD 45.00 mn in December 2023, led by Trinity Capital. Neurolens has maintained a consistent focus on its core mission to improve eye care without any notable pivots or changes in business operations since its inception.Neurolens specializes in advanced eye misalignment treatment through its innovative product offerings, primarily focusing on contoured prism lenses designed to alleviate a variety of debilitating symptoms associated with eye misalignment. These lenses aim to provide relief from headaches, eye strain, neck and shoulder pain, dizziness, dry eye, and light sensitivity. The company's core product, Neurolens, employs a unique technology that incorporates contoured prism technology to restore comfortable alignment of the eyes, thereby enhancing visual comfort and overall quality of life for patients. Neurolens primarily targets adults, as studies indicate that up to 80% of this demographic experiences issues related to eye misalignment. The company markets its products across several geographical regions, including North America and select markets in Europe, ensuring a wide reach to both optometrists and patients seeking effective solutions for their visual discomfort.Neurolens operates on a business model that includes both direct-to-consumer and B2B transactions, where the company partners with optometrists and eye care professionals to distribute its products. The transaction structure typically involves optometrists recommending Neurolens to patients who are experiencing symptoms of eye misalignment and subsequently providing the lenses during consultations. This model fosters a collaborative approach to patient care, ensuring that consumers receive tailored solutions for their eye health needs. While specific pricing details for Neurolens products are not disclosed, the company likely offers various pricing plans that cater to both individual consumers and optometry practices. This ensures accessibility and aligns with the goal of providing high-quality, effective eye care solutions.In December 2023, Neurolens secured USD 45.00 mn in growth funding led by Trinity Capital. The company plans to leverage this funding to expand its Neurolens N3 devices in optometry throughout the United States and Canada. This expansion aims to enhance their product offerings and reach more patients suffering from eye misalignment issues.

## Funding rounds

- Series E, Sep 1, 2022, $68M — Bluestem Capital Company, MVM Partners, Falcon Vision

## Investors

- Bluestem Capital Company (https://capitalatlas.ai/funds/bluestem-capital-company) — Series E
- MVM Partners (https://capitalatlas.ai/funds/mvm-partners) — Series E
- Falcon Vision — Series E